CollPlant Biotechnologies Ltd. logo
CollPlant Biotechnologies Ltd. CLGN
$ 4.12 1.98%
report update icon

Quarterly report 2025-Q4
added 05-29-2026

CollPlant Biotechnologies Ltd. General and Administrative Expenses | CLGN

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.
What these expenses include
  • Salaries of administrative staff (executives, HR, accountants, legal personnel)
  • Office rent and utilities
  • Office equipment and IT infrastructure
  • Professional services (auditors, lawyers, consultants)
  • Insurance
  • General administrative travel and representation expenses
What the metric indicates
  • Cost control
    A high level of such expenses may indicate inefficient management or an overly complex structure
  • Profitability
    Reducing administrative expenses while maintaining stable revenue increases operating profit
  • Comparative analysis
    Investors can compare this metric as a percentage of revenue among companies in the same industry
  • Business flexibility
    Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses CollPlant Biotechnologies Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
4.83 M 5.63 M 6 M 6.74 M 5.94 M 4.62 M 3.66 M 12.5 M 2.38 M 2.86 M 1.77 M 945 K 1.01 M 1.28 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
12.5 M 945 K 4.3 M

Quarterly General and Administrative Expenses CollPlant Biotechnologies Ltd.

2025-Q4 2025-Q2 2025-Q1 2024-Q4 2024-Q2 2024-Q1 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
4.83 M 1.16 M - 5.63 M 1.42 M - 6 M 1.32 M - - - - - - 1.42 M - - - 986 K - - - 820 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
6 M 820 K 2.62 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer General and Administrative Expenses Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
23.4 M $ 51.7 1.83 % $ 1.5 B usaUSA
Allakos Allakos
ALLK
38.8 M - - $ 28.6 M usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
79.4 M $ 3.73 3.61 % $ 258 M britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
16.6 M $ 1.89 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
33.3 M - -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
22.5 M - - $ 401 M usaUSA
Rezolute Rezolute
RZLT
29.2 M $ 3.94 1.87 % $ 299 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
29.9 M - -14.46 % $ 27.9 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
3.14 M $ 2.52 1.17 % $ 6.21 B israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
1.15 B $ 61.35 0.06 % $ 11.8 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
27.8 M $ 9.64 0.46 % $ 449 M usaUSA
BioNTech SE BioNTech SE
BNTX
514 M $ 99.26 0.81 % $ 24 B germanyGermany
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
30.7 M - - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
14.7 M - -15.0 % $ 3.04 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
38.4 M $ 3.63 3.93 % $ 795 M britainBritain
Amryt Pharma plc Amryt Pharma plc
AMYT
92 M - - $ 621 M britainBritain
G1 Therapeutics G1 Therapeutics
GTHX
71.1 M - - $ 370 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
3.66 M $ 2.17 0.46 % $ 3.57 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
20.8 M $ 14.24 0.35 % $ 1.27 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
36.2 M $ 3.03 0.3 % $ 251 M usaUSA
Codexis Codexis
CDXS
47.1 M $ 1.37 1.45 % $ 119 M usaUSA
Cerus Corporation Cerus Corporation
CERS
80.9 M $ 2.61 0.38 % $ 497 M usaUSA
AbbVie AbbVie
ABBV
14 B $ 265.12 0.09 % $ 469 B usaUSA
Humanigen Humanigen
HGEN
15.6 M - -81.12 % $ 4.28 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
101 M $ 1.17 1.48 % $ 137 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
83.2 M $ 12.65 2.76 % $ 3.78 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
65 M $ 5.43 2.65 % $ 288 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
43.8 M $ 31.48 1.16 % $ 2.09 B usaUSA
Фармсинтез Фармсинтез
LIFE
24.1 M - - - russiaRussia
Cellectar Biosciences Cellectar Biosciences
CLRB
11.5 M $ 2.08 0.48 % $ 5.43 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
50.4 M - - $ 76.9 M usaUSA
IMV IMV
IMV
17 M - - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
28.2 M - - $ 123 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
15.7 M - - $ 231 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
131 M - - $ 12.2 B usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
3.96 M $ 1.15 1.67 % $ 13 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
191 M $ 84.95 0.13 % $ 7.99 B usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
67.6 M $ 22.64 0.85 % $ 717 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
449 M $ 118.51 4.93 % $ 12.3 B usaUSA
Chimerix Chimerix
CMRX
22.2 M - - $ 756 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
15.2 M $ 7.45 0.19 % $ 99.2 M usaUSA
Curis Curis
CRIS
14 M $ 0.88 0.85 % $ 11.6 M usaUSA
CorMedix CorMedix
CRMD
68.2 M $ 7.77 1.04 % $ 560 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
73.5 M $ 55.7 0.23 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
9.25 M $ 11.8 8.21 % $ 932 M usaUSA
Champions Oncology Champions Oncology
CSBR
11.2 M $ 4.95 0.38 % $ 68.5 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
15.9 M $ 4.88 0.62 % $ 935 M canadaCanada
Cue Biopharma Cue Biopharma
CUE
16.2 M $ 32.85 3.6 % $ 3.11 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
8.92 M $ 1.72 2.38 % $ 13.8 M usaUSA